Cytotoxic and genotoxic effects of131I and60Co in follicular thyroid cancer cell (WRO) with and without recombinant human thyroid-stimulating hormone treatment
| Autor: | Paolo Bartolini, Kayo Okazaki, Daniel Perez Vieira, Maria Teresa C.P. Ribela, Flávia Gomes Silva Valgôde, Márcia Augusta da Silva |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Epidemiology Health Toxicology and Mutagenesis Thyroid Cancer Biology medicine.disease_cause medicine.disease 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Endocrinology medicine.anatomical_structure 030220 oncology & carcinogenesis Radioresistance Internal medicine Micronucleus test medicine Cancer research Cytotoxic T cell Follicular thyroid cancer Thyroid cancer Genetics (clinical) Genotoxicity |
| Zdroj: | Environmental and Molecular Mutagenesis. 58:451-461 |
| ISSN: | 0893-6692 |
| DOI: | 10.1002/em.22099 |
| Popis: | Normally, differentiated thyroid cancer (DTC) tends to be biologically indolent, highly curable and has an excellent prognosis. However, the treatment may fail when the cancer has lost radioiodine avidity. The present study was carried out in order to evaluate the cytotoxic and genotoxic effects of 131 I and 60 Co and radioiodine uptake in WRO cells, derived from DTC, harboring the BRAFV600E mutation. WRO cells showed a relatively slow cell cycle of 96.3 h with an unstable karyotype containing various double minutes. The genotoxicity assay (micronucleus test) showed a relative high radioresistance to 131 I (0.07-3.70 MBq/mL), independent of treatment with recombinant human thyroid-stimulating hormone (rhTSH). For the cytotoxicity assay, WRO cells were also relatively resistant to 60 Co (range: 0.2-8.3 Gy), but with a gradual decrease of viability as a function of time for higher doses (20 and 40 Gy, starting from the fifth to sixth day). For internal irradiation with 131 I, WRO cells showed a decline in viability at radioactive concentration higher than 1.85 MBq/mL; this was even more effective at 3.70 MBq/mL, but only when preceded by rhTSH, in coincidence with the highest level of 131 I uptake. These data show promising results, since the loss of the ability of thyroid cells to concentrate radioiodine is considered to be one of the main factors responsible for the failure of 131 I therapy in patients with DTC. The use of tumor-derived cell lines as a model for in vivo tumor requires, however, further investigations and deep evaluation of the corresponding in vivo effects. Environ. Mol. Mutagen. 58:451-461, 2017. © 2017 Wiley Periodicals, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text